Trial Profile
SecOnd-line Chemotherapy with RAmucirumab +/- pacliTaxel in Elderly advanced gastric or gastroesophageal junction cancer patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms SOCRATE
- 16 Aug 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 16 Aug 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 16 Aug 2023 Status changed from recruiting to active, no longer recruiting.